EResearchTechnology, Inc. Q2 2010 Earnings Call Transcript
The second quarter saw a fundamental strategic shift in our business. The acquisition of RS has significantly increased market opportunity and has given us a much broader set of products and services to offer to the clinical trial industry. This has enhanced our platform by enabling us to deliver additional products and services in the future.
Specifically, we now have an industry leading suite of products in respiratory diagnostics for clinical trials that encompass the primary respiratory diseases of COPD, asthma, and cystic fibrosis. We have added significant additional capabilities to our ePRO product and service lines by adding a PDA like device called VIAPad as well as a pen based device called VIAPen. We’ve also added a whole new dimension to the products and services that we can offer our own proprietary diagnostic devices for clinical trials.
These devices give us a great land expanded approach to offer and customize product solutions using multiple modalities for the acquisition of important information in clinical trials. We believe this offers us a key strategic competitive advantage in our industry. These devices also support and enable our future strategy of providing products and services into the healthcare industry.
We’ve received a very favorable reactions and clients, investors, and other stakeholders regarding the potentials for this acquisition on our future business, many clients have expressed support for buying multiple services from one vendor, especially vendors with a strong reputation for quality and services that ERT and RS have in the marketplace.Other advantages cited by clients are bringing together with a combined medical expertise of two of the leading providers of technology and services used in clinical trials, the increased resources that the company can bring, the increased global footprint of the combined company, and the advantages of working with the company whose sole current focus is on clinical trials.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV